Listen to the article
Federal prosecutors have filed a civil complaint against two St. Louis doctors and their affiliated businesses, alleging they orchestrated a Medicare fraud scheme involving electrical stimulation treatments and vitamin injections, according to the U.S. Attorney’s Office for the Eastern District of Pennsylvania.
The complaint, filed under the False Claims Act, names Dr. Michael Glickert and Dr. Joseph Novof, along with their medical practice, The Vanguard Clinic LLC, and a related distributorship, Fleur de Lis LLC. Prosecutors claim the defendants submitted fraudulent claims to federal healthcare programs for treatments using the RST-Sanexas neoGEN-series device and associated vitamin injections.
According to federal authorities, Medicare and other federal healthcare programs do not cover electrical nerve stimulation treatments provided in outpatient settings for pain management, nor do they reimburse for vitamin injections administered alongside these treatments.
The complaint alleges that beginning in late 2018, Dr. Glickert actively promoted these treatments as Medicare-reimbursable and provided billing guidance to other healthcare providers. Prosecutors assert that Glickert was aware the billing practices could be considered fraudulent but continued submitting claims regardless.
Dr. Novof faces additional allegations of falsely certifying that vitamin injections were medically necessary despite not knowing their contents, a serious violation of medical standards and federal healthcare regulations.
U.S. Attorney David Metcalf emphasized the significance of this case, stating, “Our office continues to lead the national charge to hold alleged fraudsters accountable for improper Sanexas billing.” He added that his office will “continue working closely with our partners to pursue any other providers who inappropriately billed for these devices and caused false claims to be submitted.”
This case represents part of a broader nationwide investigation into questionable billing practices involving electrical stimulation devices. The investigation has already yielded multiple settlements and financial recoveries totaling millions of dollars, reflecting the federal government’s increased scrutiny of medical device billing.
Healthcare fraud involving electrical stimulation devices has become a particular focus for federal investigators in recent years. These devices, which deliver electrical impulses to treat various forms of pain and nerve conditions, have been subject to improper billing practices across multiple jurisdictions, according to industry experts.
The investigation involves significant interagency cooperation, including the Department of Justice’s Civil Division, the Centers for Medicare & Medicaid Services (CMS), and the Department of Health and Human Services Office of Inspector General.
It’s worth noting that electrical stimulation technology itself remains a legitimate treatment option when properly prescribed and billed. However, the reimbursement rules surrounding such treatments are complex, with specific guidelines about which settings and conditions qualify for federal healthcare program coverage.
The complaint filed in Philadelphia is particularly significant as it targets not just individual practitioners but also the business entities allegedly involved in the scheme. This approach reflects the government’s strategy of addressing healthcare fraud at both the clinical and organizational levels.
As with all civil complaints, the filing represents allegations only, and no determination of liability has been made against the defendants at this time. The parties named will have the opportunity to respond to the allegations through the legal process.
If found liable under the False Claims Act, the defendants could face substantial financial penalties, including triple damages for amounts fraudulently billed to government healthcare programs.
Federal agencies continue to encourage healthcare professionals and patients to report suspected healthcare fraud through established whistleblower channels.
Fact Checker
Verify the accuracy of this article using The Disinformation Commission analysis and real-time sources.
15 Comments
It’s disheartening to see healthcare providers betraying the public trust in this way. Patients deserve quality, ethical care – not schemes to line the pockets of unscrupulous providers. I hope the government’s lawsuit is successful.
This case raises questions about the role of physician-owned distributorships in the medical supply chain. Were there conflicts of interest or kickbacks involved? Ensuring proper safeguards is key to preventing abuse of federal programs.
This alleged billing scheme sounds very concerning. It’s troubling to see healthcare providers taking advantage of federal programs like this. I hope the government can get to the bottom of it and recoup any fraudulent payments.
This case serves as a cautionary tale about the need for vigilance in the medical industry. Healthcare providers must be held to the highest ethical standards to maintain public trust. Rigorous oversight and enforcement are essential.
Billing fraud undermines the entire healthcare system. It’s crucial that the government comes down hard on providers who take advantage of federal programs. Protecting Medicare’s solvency should be a top priority.
Misusing medical devices and submitting false claims for reimbursement is a serious offense. The government is right to take action and hold these doctors accountable. Protecting the integrity of Medicare is critical.
As a taxpayer, I’m glad to see the government taking decisive action to recoup fraudulent Medicare payments. Protecting public funds from exploitation should be a top priority. Hopefully this sends a strong message to deter future misconduct in the healthcare sector.
I’m curious to know if this alleged scheme involved any kickbacks or other financial incentives for the doctors. Understanding the full scope of the misconduct is important for developing effective policies to prevent future fraud.
This case highlights the need for better education and training around proper billing practices, especially for new or experimental treatments. Clearer guidelines could help prevent inadvertent errors as well as intentional fraud.
The details provided raise a lot of questions. What specific treatments were billed as Medicare-reimbursable, and how did the doctors mislead other providers? More transparency around the scheme would be helpful to understand the full scope of the alleged fraud.
I’m curious to learn more about the specific devices and treatments involved. What makes them ineligible for Medicare reimbursement, and how widespread is this problem in the healthcare sector? Transparency around these issues is important.
This case highlights the importance of robust auditing and oversight of Medicare billing practices. Clear guidelines and enforcement are needed to prevent abuse. Taxpayers should not be subsidizing fraudulent medical treatments.
It’s important that the medical industry maintains high ethical standards. This case highlights the need for robust oversight and enforcement to prevent fraud and abuse. Taxpayers should not be footing the bill for these kinds of schemes.
It’s troubling to see medical professionals abusing their position of trust. Patients should be able to rely on their doctors to provide ethical, evidence-based care – not engage in fraudulent billing practices. This lawsuit is an important step in restoring that trust.
As a taxpayer, I’m glad to see the government taking action to recoup fraudulent Medicare payments. Protecting public funds from exploitation should be a top priority. Hopefully this sends a strong message to deter future misconduct.